121 related articles for article (PubMed ID: 7750282)
1. Clinical trial with Nestorone subdermal contraceptive implants.
Díaz S; Schiappacasse V; Pavez M; Zepeda A; Moo-Young AJ; Brandeis A; Lähteenmäki P; Croxatto HB
Contraception; 1995 Jan; 51(1):33-8. PubMed ID: 7750282
[TBL] [Abstract][Full Text] [Related]
2. Ovarian function during use of Nestorone(R) subdermal implants.
Brache V; Massai R; Mishell DR; Moo-Young AJ; Alvarez F; Salvatierra AM; Cochon L; Croxatto H; Robbins A; Faundes A
Contraception; 2000 Mar; 61(3):199-204. PubMed ID: 10827334
[TBL] [Abstract][Full Text] [Related]
3. A contraceptive subdermal implant releasing the progestin ST-1435: ovarian function, bleeding patterns, and side effects.
Laurikka-Routti M; Haukkamaa M
Fertil Steril; 1992 Dec; 58(6):1142-7. PubMed ID: 1459263
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial with 3-keto-desogestrel subdermal implants.
Díaz S; Pavez M; Moo-Young AJ; Bardin CW; Croxatto HB
Contraception; 1991 Oct; 44(4):393-408. PubMed ID: 1756627
[TBL] [Abstract][Full Text] [Related]
5. A detailed analysis of menstrual blood loss in women using Norplant and Nestorone progestogen-only contraceptive implants or vaginal rings.
Fraser IS; Weisberg E; Minehan E; Johansson ED
Contraception; 2000 Apr; 61(4):241-51. PubMed ID: 10899479
[TBL] [Abstract][Full Text] [Related]
6. Ovarian function during use of vaginal rings delivering three different doses of Nestorone.
Brache V; Mishell DR; Lahteenmaki P; Alvarez F; Elomaa K; Jackanicz T; Faundes A
Contraception; 2001 May; 63(5):257-61. PubMed ID: 11448466
[TBL] [Abstract][Full Text] [Related]
7. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.
Fraser IS; Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Tsong YY; Sivin I
Contraception; 2005 Jul; 72(1):40-5. PubMed ID: 15964291
[TBL] [Abstract][Full Text] [Related]
8. Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study.
Haukkamaa M; Laurikka-Routti M; Heikinheimo O; Moo-Young A
Contraception; 1992 Jan; 45(1):49-55. PubMed ID: 1591921
[TBL] [Abstract][Full Text] [Related]
9. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
10. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women.
Massai MR; Díaz S; Quinteros E; Reyes MV; Herreros C; Zepeda A; Croxatto HB; Moo-Young AJ
Contraception; 2001 Dec; 64(6):369-76. PubMed ID: 11834236
[TBL] [Abstract][Full Text] [Related]
11. Correlation of endocrine profiles with bleeding patterns during use of Nestorone contraceptive implants.
Faúndes A; Alvarez F; Brache V; Cochón L; Tejada AS; Moo-Young A
Hum Reprod; 1999 Dec; 14(12):3013-7. PubMed ID: 10601089
[TBL] [Abstract][Full Text] [Related]
12. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
[TBL] [Abstract][Full Text] [Related]
13. Subdermal progestin implant (Nestorone) in the treatment of endometriosis: clinical response to various doses.
Ylänen K; Laatikainen T; Lähteenmäki P; Moo-Young AJ
Acta Obstet Gynecol Scand; 2003 Feb; 82(2):167-72. PubMed ID: 12648180
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study of Nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception.
Croxatto HB; Brache V; Massai R; Alvarez F; Forcelledo ML; Pavez M; Cochon L; Salvatierra AM; Faundes A
Contraception; 2006 Jan; 73(1):46-52. PubMed ID: 16371294
[TBL] [Abstract][Full Text] [Related]
15. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
16. Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant.
Bahamondes L; Hidalgo M; Petta CA; Diaz J; Espejo-Arce X; Monteiro-Dantas C
J Reprod Med; 2003 Aug; 48(8):637-40. PubMed ID: 12971147
[TBL] [Abstract][Full Text] [Related]
17. Plasma levonorgestrel and progesterone levels in women treated with silastic covered rods containing levonorgestrel.
Croxatto HB; Díaz S; Brandeis A; Pavez M; Johansson ED
Contraception; 1985 Jun; 31(6):643-54. PubMed ID: 3930143
[TBL] [Abstract][Full Text] [Related]
18. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial.
Sivin I; Mishell DR; Alvarez F; Brache V; Elomaa K; Lähteenmäki P; Massai R; Miranda P; Croxatto H; Dean C; Small M; Nash H; Jackanicz TM
Contraception; 2005 Feb; 71(2):122-9. PubMed ID: 15707562
[TBL] [Abstract][Full Text] [Related]
19. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
20. Two-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women.
Sivin I; Croxatto H; Bahamondes L; Brache V; Alvarez F; Massai R; Schechter J; Ranta S; Kumar N; Wu E; Tejeda AS; Reyes V; Travers E; Allen A; Moo-Young A
Contraception; 2004 Feb; 69(2):137-44. PubMed ID: 14759619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
